Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Otsuka Holdings (4578 JP): Strong 1H Result; FY Guidance Revision; Approaching Next Level Growth

Otsuka Holdings (4578 JP): All Eyes on Sibeprenlimab in Likely Stable 2026, More Approvals Awaited

Otsuka Holdings (4578 JP): Rexulti, Abilify Gain Further Traction in 1Q26, Guidance Reiterated

Otsuka Holdings (4578 JP): Rexulti, Abilify Drive 2025 Guidance Upward, All Eyes on Sibeprenlimab

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/otsuka-holdings-co-ltd" target="_blank" data-smartkarma-citation="entities:12292:1" rel="noopener">Otsuka Holdings (4578 JP)</a> presented positive 12-month eGFR data from a pre-specified interim analysis of the Phase 3 trial of Voyxact (sibeprenlimab-szsi) for the treatment of IgA nephropathy in adults.</li>
<li>In 2H26, the company plans to submit a regulatory application for full approval based on the eGFR data, as well as an application for auto-injector formulation.</li>
<li>New drugs like sibeprenlimab will help drive growth in the medium to long term. Top selling drugs are also steadily gaining traction. We recommend to Hold the stock for now.</li>
</ul>



Otsuka Holdings (4578 JP) presented positive 12-month eGFR data from a pre-specified interim analysis of the Phase 3 trial of Voyxact (sibeprenlimab-szsi) for the treatment of IgA nephropathy in adults.
In 2H26, the company plans to submit a regulatory application for full approval based on the eGFR data, as well as an application for auto-injector formulation.
New drugs like sibeprenlimab will help drive growth in the medium to long term. Top selling drugs are also steadily gaining traction. We recommend to Hold the stock for now.


Otsuka Holdings (4578 JP): Voyxact Positive Trial Data Augur Well For the Future